119 related articles for article (PubMed ID: 11695241)
1. Effective anti-tumor immunity induced in mice by a two-step vaccination protocol.
Martino A; Vismara D; Cicconi R; Delpino A; Ivanyi J; Colizzi V; Cassol M; Fraziano M; Piselli P
In Vivo; 2001; 15(5):425-8. PubMed ID: 11695241
[TBL] [Abstract][Full Text] [Related]
2. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
3. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
Provinciali M; Argentati K; Tibaldi A
Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
[TBL] [Abstract][Full Text] [Related]
5. Alloantigen-activated lymphocytes from mice bearing a spontaneous "nonimmunogenic" adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity.
Giovarelli M; Santoni A; Forni G
J Immunol; 1985 Nov; 135(5):3596-603. PubMed ID: 3930610
[TBL] [Abstract][Full Text] [Related]
6. Tumor cells expressing a recall antigen are powerful cancer vaccines.
Schweighoffer T
Eur J Immunol; 1996 Nov; 26(11):2559-64. PubMed ID: 8921939
[TBL] [Abstract][Full Text] [Related]
7. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
[TBL] [Abstract][Full Text] [Related]
8. Therapy of lung metastases through combined vaccination with carcinoma cells engineered to release IL-13 and IFN-gamma.
De Giovanni C; Nicoletti G; Landuzzi L; Rossi I; Astolfi A; Ricci C; Di Carlo E; Musiani P; Forni G; Fradelizi D; Nanni P; Lollini PL
Gene Ther; 2001 Nov; 8(22):1698-704. PubMed ID: 11892837
[TBL] [Abstract][Full Text] [Related]
9. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
[TBL] [Abstract][Full Text] [Related]
10. Surrogate tumor antigen vaccination induces tumor-specific immunity and the rejection of spontaneous metastases.
Lewis JD; Shearer MH; Kennedy RC; Bright RK
Cancer Res; 2005 Apr; 65(7):2938-46. PubMed ID: 15805297
[TBL] [Abstract][Full Text] [Related]
11. Rejection of mammary adenocarcinoma cell tumors in DBA/2 mice immunocompromised by thymectomy and treatment with antithymocyte serum.
Likhite VV
J Immunol; 1975 Jun; 114(6):1736-42. PubMed ID: 1092759
[TBL] [Abstract][Full Text] [Related]
12. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
Chen PW; Uno T; Ksander BR
Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898
[TBL] [Abstract][Full Text] [Related]
13. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
Grangeon C; Cormary C; Douin-Echinard V; Favre G; Couderc B; Tilkin-Mariamé AF
Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445
[TBL] [Abstract][Full Text] [Related]
14. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules.
Cormary C; Gonzalez R; Faye JC; Favre G; Tilkin-Mariamé AF
Cancer Gene Ther; 2004 Jul; 11(7):497-507. PubMed ID: 15153937
[TBL] [Abstract][Full Text] [Related]
15. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
16. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
Luo Y; Zhou H; Mizutani M; Mizutani N; Liu C; Xiang R; Reisfeld RA
Cancer Res; 2005 Apr; 65(8):3419-27. PubMed ID: 15833877
[TBL] [Abstract][Full Text] [Related]
17. Increased immunogenicity of a spontaneous variant clone of the 13762A rat mammary adenocarcinoma.
Kreider JW; Bartlett GL
J Natl Cancer Inst; 1985 Jul; 75(1):141-9. PubMed ID: 3859687
[TBL] [Abstract][Full Text] [Related]
18. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma.
Cavallo F; Di Pierro F; Giovarelli M; Gulino A; Vacca A; Stoppacciaro A; Forni M; Modesti A; Forni G
Cancer Res; 1993 Nov; 53(21):5067-70. PubMed ID: 8221636
[TBL] [Abstract][Full Text] [Related]
19. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
20. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus.
Rosato A; Dalla Santa S; Zoso A; Giacomelli S; Milan G; Macino B; Tosello V; Dellabona P; Lollini PL; De Giovanni C; Zanovello P
Cancer Res; 2003 May; 63(9):2158-63. PubMed ID: 12727834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
